SUDEEPPHRM · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 59/100 — Quality 96 · Valuation 8
| Share price | ₹866.45 |
| Market cap | ₹9,310 Cr |
| P/E ratio | 55.2 |
| P/B ratio | 10.4 |
| ROE | 28.1% |
| ROCE | 34.6% |
| Dividend yield | 0.18% |
| Book value | ₹79.16 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹642 Cr | ₹174 Cr | 35.0% |
| 2025 | ₹502 Cr | ₹139 Cr | 38.0% |
| 2024 | ₹459 Cr | ₹133 Cr | 40.0% |
| 2023 | ₹429 Cr | ₹62 Cr | 21.0% |
| 2022 | ₹343 Cr | ₹50 Cr | 20.0% |
Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in United States, Europe, United Kingdom, and Latin America. The company provides mineral salts, such as calcium, zinc, iron, potassium, magnesium, sodium, and copper to a range of health-focused applications; and calcium carbonate, which is used as an active pharmaceutical ingredient for various therapeutic applications. It also offers micronutrient premixes, encapsulated ingredients, liposomal and spray-dried formats, granulated minerals, and triturated ble